After the FDA questioned the safety of two CAR-T therapies, members of the agency’s Oncologic Drugs Advisory Committee voted unanimously to recommend Carvykti, made by Janssen Biotech, and voted 8-3 in favor for Abecma, from Bristol-Myers Squibb K.K.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
